Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07559903). This is a study registration, not published results. Lead sponsor: Emory University. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 5000 participants (ESTIMATED). Conditions: Coronary Artery Disease. Primary outcome measures: Incidence of Target Lesion Failure (TLF) , At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge; Mortality and Myocardial Infarction , At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge; Number of any repeat Revascularization , At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge; Incidence of Target Vessel Failure (TVF) and definite/probable vessel thrombosis , At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge; Number of bleeding events , At hospital discharge, 30 days, 6 months, and 12 months post-discharge, then yearly up to 5 years post-discharge. Brief summary: The primary objective of this protocol is to develop a comprehensive, multicenter international prospective registry to capture long-term clinical outcomes for adult patients undergoing percutaneous coronary intervention (PCI) with drug-coated balloons (DCB) for de novo coronary artery disease.